The global NAFLD epidemic

By R. Loomba, A. Sanyal. Nature Reviews Gastroenterology &Hepatology, 2013

1,687 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Epidemiology, Hepatology

View Paper: https://www.semanticscholar.org/paper/c789affff9cecc26dd8c979432f05c3451a3e494

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. Z. Younossi
2. S. Friedman
3. R. Loomba
4. Gerald I. Shulman
5. A. Sanyal
6. Megan H. Bair-Merritt
7. G. Targher
8. M. Rinella

In Epidemiology

1. Z. Younossi
2. S. Friedman
3. R. Loomba
4. Gerald I. Shulman
5. A. Sanyal
6. Koji Yamano
7. N. Matsuda
8. Miyuki Sato

In Hepatology

1. S. Friedman
2. Z. Younossi
3. R. Loomba
4. Gerald I. Shulman
5. A. Sanyal
6. C. Estes
7. Jasmin A. Tiro
8. Amit G. Singal

Citations in the corpus

• Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. (2017, background): “Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide [1-3], affecting up to 25% of the global population [4].”
• Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease (2017, background): “Nonalcoholic fatty liver disease (NAFLD) is a growing cause of chronic liver disease globally.((1-3)) Characterized by excessive fat deposition in the liver that is not attributable to consumption of alcohol,((4)) the most common risk factors include obesity, insulin resistance, and the features of”
• Early Detection, Curative Treatment, and Survival Rates for Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis: A Meta-analysis (2014, background): “Subset analyses were planned for predefined variables, including (i) location of study (Asia versus Europe versus United States), (ii) study period (prior to 1990s versus 1990s versus 2000s), (iii) proportion of Child Pugh C cirrhosis (,10% versus $ 10%), (iv) type of surveillance tests (ultrasound ”
• Mechanisms and disease consequences of nonalcoholic fatty liver disease (2021, background): “Nonalcoholic fatty liver disease (NAFLD) is emerging as the leading chronic liver disease worldwide (Loomba and Sanyal, 2013; Younossi et al., 2016).”
• Morbidity and mortality associated with obesity. (2017, background): “NAFLD is the most common cause of chronic liver disease in the United States (55,56).”
• Role of Dietary Fructose and Hepatic de novo Lipogenesis in Fatty Liver Disease (2016, background): “Nonalcoholic fatty liver disease (NAFLD) is a liver manifestation of metabolic syndrome, and it is estimated to affect 1 billion individuals worldwide [3].”
• Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus (2016, neutral): “N fatty liver disease (NAFLD) is reaching epidemic proportions worldwide (1) and is the most common chronic liver condition in obese patients with prediabetes or type 2 diabetes mellitus (T2DM).”
• Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update (2019, background): “Hence, NASH is indeed an important cause of chronic liver disease [61].”
• Gut Microbiota-Derived Tryptophan Metabolites Modulate Inflammatory Response in Hepatocytes and Macrophages (2018, neutral): “It encompasses a spectrum of disorders from simple steatosis, by itself a benign condition, to non-alcoholic steatohepatitis (NASH), characterized by intrahepatic inflammation, hepatocellular ballooning, and progressive fibrosis (Loomba and Sanyal, 2013).”